Skip to main content
LNAI
NASDAQ Life Sciences

Lunai Bioworks Announces 1-for-8 Reverse Stock Split to Regain Nasdaq Compliance

Arie Shkolnikov · Analysis by Wiseek AI
More coverage: Biotech Stocks · Healthcare
Sentiment info
Negative
Importance info
8
Price
$0.255
Mkt Cap
$9.075M
52W Low
$0.151
52W High
$4.496
52W Position info
68% above low
Off High info
94% below high
Rel. Volume
Market data snapshot near publication time

LNAI sits 68% above its 52-week low of $0.151.

Summary

Lunai Bioworks will execute a 1-for-8 reverse stock split on May 22, 2026, a move aimed at boosting its share price to meet Nasdaq's minimum bid requirement and avoid delisting.


Key Events · Corporate Governance and Compliance · LNAI

  • Reverse Stock Split Finalized

    Lunai Bioworks announced a 1-for-8 reverse stock split, effective May 22, 2026. This follows shareholder approval on May 8, 2026, for a split ratio between 1-for-3 and 1-for-30.

  • Nasdaq Compliance Effort

    The primary purpose of the split is to increase the stock price above $1.00 to regain compliance with Nasdaq Listing Rule 5550(a)(2) and avoid delisting.

  • Previous Reverse Split History

    This marks the second reverse stock split for the company, following a 1-for-10 split on September 30, 2025, highlighting ongoing challenges with its share price.


Analysis · LNAI · Life Sciences

This 8-K announces the final 1-for-8 reverse stock split ratio and its effective date of May 22, 2026. While shareholders previously approved a reverse split, this filing provides the definitive terms. The split is a critical step for Lunai Bioworks to increase its per-share price and meet Nasdaq's minimum bid price requirement, following multiple delisting notices and a prior reverse split in 2025. Failure to comply would result in delisting, making this a necessary but negative action reflecting ongoing challenges.

How filings like this one have moved

In the 30 days to Nov 15, 2026, 48.2% of the 1980 measured filings Wiseek scored 8 moved their stock by 5% or more by the next session's close. The median move was -0.20%. These are measured outcomes after filings of this importance, not a forecast for this one.

Measured one observation per ticker per day, after exclusions. Current figures: Filing Impact Tracker · open dataset

At the time of this filing, LNAI was trading at $0.25 on NASDAQ in the Life Sciences sector, with a market capitalization of approximately $9.1M. The 52-week trading range was $0.15 to $4.50. This filing was assessed with negative market sentiment and an importance score of 8 out of 10.

View Main SEC Filing

Price Chart

Share this article

Copied!

LNAI - Latest Insights

LNAI
Oct 23, 2026, 2:21 AM EDT
Source: Seeking Alpha
Importance Score:
9
Price at Filing: $0.380
Real-time Price: $0.091 info
Change: -$0.289 (-76%) info
Market Cap: $829.678K info
LNAI
Oct 22, 2026, 9:38 PM EDT
Filing Type: 8-K
Importance Score:
9
Price at Filing: $0.3111
Real-time Price: $0.091 info
Change: -$0.2201 (-71%) info
Market Cap: $829.678K info
LNAI
Oct 13, 2026, 4:55 PM EDT
Filing Type: 10-K
Importance Score:
9
Price at Filing: $1.04
Real-time Price: $0.091 info
Change: -$0.949 (-91%) info
Market Cap: $829.678K info
LNAI
Oct 09, 2026, 2:00 PM EDT
Filing Type: 8-K
Importance Score:
8
Price at Filing: $1.18
Real-time Price: $0.091 info
Change: -$1.08 (-92%) info
Market Cap: $829.678K info
LNAI
Sep 22, 2026, 9:20 AM EDT
Source: PR Newswire
Importance Score:
7
Price at Filing: $2.40
Real-time Price: $0.091 info
Change: -$2.31 (-96%) info
Market Cap: $829.678K info